Single primary endpoint defined as three cardinal symptoms at 24 weeks Company to host conference call at 5:00 PM ET today WATERTOWN, Mass. --(BUSINESS WIRE)--Jun. 8, 2021-- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to

Partnership opens expanded opportunity for LYR-210 to address chronic rhinosinusitis, a disease affecting approximately 88 million adults in China   WATERTOWN, Mass. & SHANGHAI & PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 2, 2021-- Lyra Therapeutics, Inc.

WATERTOWN, Mass. --(BUSINESS WIRE)--Jun. 1, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)

WATERTOWN, Mass. --(BUSINESS WIRE)--May 24, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)

- Presented positive full data from LANTERN Phase 2 study of LYR-210 at COSM – - Appointed Robert Kern , MD, as Chief Medical Officer - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass. --(BUSINESS WIRE)--May 11, 2021-- Lyra Therapeutics, Inc.

WATERTOWN, Mass. --(BUSINESS WIRE)--May 6, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)

WATERTOWN, Mass. --(BUSINESS WIRE)--Apr. 27, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)

New data presented includes: - First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) - - LYR-210 (7500µg) decreased ethmoid

- LYR-210 is Lyra’s lead product candidate for chronic rhinosinusitis - WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 29, 2021-- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions

- Positive Topline Results for LANTERN Phase 2 Study of LYR-210- - Robert Kern , MD, appointed Chief Medical Officer - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 9, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics